M&A highlights from last week…👇
YTD Summary:
Number Announced: 28
Q1 2024 # Announced: 18
Q2 2024 # Announced: 10
Mariana Oncology
Acquired By: Novartis
Announcement Date: May 2, 2024
Acquisition Price: $1B upfront + up to $750M milestone payment
Acquisition Date (Closed): Pending
Lead Asset: MC-339
Lead Asset Stage: Preclinical
Indication: Small Cell Lung Cancers
Epygenix Therapeutics
Acquired By: Harmony Biosciences
Announcement Date: April 30, 2024
Acquisition Price: $35M upfront + up to $130M milestone payment
Acquisition Date (Closed): Pending
Lead Asset: EPX-100
Lead Asset Stage: Phase 2
Lead Asset Indication: Dravet Syndrome
Deciphera Pharmaceuticals
Acquired By: ONO Pharmaceuticals
Announcement Date: April 29, 2024
Acquisition Price: $2.4B
Acquisition Date (Closed): Pending
Lead Asset: Ripretinib
Lead Asset Stage: Approved
Lead Asset Indication: Gastrointestinal stromal tumor
---
Get a list of all recently funded companies with deeper info to help your sales/BD activities. Contact us to learn more
Article History:
RF, DV, DG (05/03/24)
This article is not investment or legal advice.
Комментарии